SIRIL AROCKIAM
Open to postdoctoral and industry roles · 2026

Siril Arockiam.

Ph.D. · Postdoctoral Research Scholar, Biodesign Institute, Arizona State University

I build computational systems for cancer immunogenomics, from GPU-accelerated sequence alignment to neoepitope discovery, grounded in wet-lab validation and cGMP industry experience.

95%
Locus accuracy, GPU aligner @ 9 ms/read
5.98 nM
Top neoepitope binder, HLA‑A*68:02
<30 s
To call TB rifampicin resistance
4,324
Saliva samples, HPV16 prevalence study
100+
Molecular assays designed & validated
Research

Learned representations of biological sequence and structure

My work sits at the intersection of computational genomics and immunology. I design methods that turn raw sequencing data into decisions: which viral integration events matter, which mutated peptides an immune system can actually see, and how to read a genome fast enough to matter in the clinic.

On the systems side, I built GenoCache, a learned-embedding alignment engine that reaches 95 percent locus accuracy at 9 ms per long read on an A100, within 0.85x of minimap2's three decades of hand-tuned heuristics. On the biology side, I built an end-to-end neoepitope discovery pipeline for HPV-driven cancers, and I am extending it across TCGA cohorts to ask whether integration burden and host gene expression predict survival.

None of it is only computational. I have run the assays, sequenced the samples, and validated in the field, and I spent two years developing vaccine potency assays under cGMP at Merck. I care about methods that survive contact with real, messy biological data.

PyTorchCUDAFAISSHyenaDNA / DNABERT-2scGPTpVACtools / NetMHCpanVIRUSBreakend / GRIDSSOxford NanoporeScanpy / SeuratPython & R
FocusCancer immunogenomics & ML for genomics
Ph.D.Biological Design, ASU (2025)
NowPostdoc, Biodesign Institute
IndustryScientist II, Merck (cGMP)
Based inTempe, Arizona
Patents2 filed · 2 pending
Publications5 peer-reviewed · 5 in review/prep
Selected Work

Projects that turn sequence into decisions

Recent computational work leads off, from GPU genomics to HPV neoepitope discovery, followed by the translational diagnostics platforms behind my publications and patents. Each one shipped a working system, not just a result.

GPU Genomics · Independent2025–26

GenoCache: learned-embedding long-read aligner

A learned encoder that aligns long reads at near-minimap2 speed, no hand-tuned seeds.

A GPU-accelerated alignment engine that replaces hand-tuned seeding with a lightweight learned encoder (0.5M params, 128-D embeddings) plus FAISS vector search, DP-chaining, and edlib verification, with full SAM/CIGAR output. Built at the NVIDIA AI x Bio Hackathon and continued as independent research; awarded $15K in AWS and Modal cloud credits.

1D CNN encoderFAISS / IVF-PQfp16 tensor-core searchnumba JITedlib91.8M-vector GRCh38 index
95.0%Locus accuracy, real ONT reads
9.0 msPer read on A100 (0.85x minimap2)
4.8xSpeedup from profiling & tuning
Immunogenomics2025–26

HPV neoepitope discovery pipeline

Turns HPV integration junctions into ranked, HLA-matched immunotherapy targets.

End-to-end pipeline from whole-genome sequencing to MHC-I binding: VIRUSBreakend/GRIDSS for integration detection, OptiType for HLA typing, pVACtools and NetMHCpan for prediction. Found 9 junction-spanning neoepitopes across HPV16/18 integration hotspots (GLI2, KLF5, MYC), plus novel E6/E7 epitopes for under-studied alleles. Now scaling to TCGA-CESC/HNSC (n>600).

5.98 nMTop binder, A*68:02
9Junction neoepitopes
n>600TCGA cohort scale-up
WGSpVACtoolsNetMHCpanHLA typing
Sequencing Dx2025–26

Rapid TB drug-resistance detection

Same-visit rifampicin-resistance calls, read straight off the sequencer.

LAMP amplification coupled to Oxford Nanopore MinION with an optimized rapid library prep. Detected the rifampicin-resistance mutation S450L at 66,000x depth within 30 seconds of sequencing, with sample-to-mutation in under two hours, a route to same-visit resistance profiling in low-resource settings.

<30 sTo first resistance call
66,000xDepth at S450L
<2 hrSample to answer
LAMPNanopore MinIONrpoB / S450L
Point-of-Care Dx2020–25

SPRINT-HPV point-of-care platform

Lab-grade cervical cancer screening with no lab and no cold chain.

A microfluidic cartridge ($10–20/test) with a battery-powered detector ($200–300) for cervical cancer screening where cold-chain and labs are scarce. Field-validated on 150+ patient samples at AIIMS against Roche Cobas, with a multiplex LAMP assay covering 11 high-risk HPV types down to 2.5 copies/uL.

100%Sensitivity vs Cobas
94.5%Specificity, cervical
<60 minSample to answer
Multiplex LAMPMicrofluidicsLyophilized reagentsField-tested
Single-Cell ML2026

scFM-Bench: single-cell annotation benchmark

A benchmark for cell-type annotation on PBMC scRNA-seq comparing reference-mapping (Seurat v5, CellTypist) against MLP baselines, with a focus on how methods behave when reference panels are small. PyTorch MLP baseline reaches 0.84 macro F1; extending to single-cell foundation models (scGPT).

0.84Macro F1, held-out cells
scGPTFoundation-model track
Scanpy / AnnDataSeuratCellTypistPyTorch
Structural Immunology2026

TCR-pMHC structural analysis

Analyzed 109 TCR-pMHC crystal structures from the PDB to map CDR-loop contact patterns at the peptide interface, confirming the P4–P8 dominant contact window. Exploring whether TCR sequence features correlate with 3D binding motifs, to push immunogenicity prediction beyond binding affinity alone.

109Crystal structures
P4–P8Contact window mapped
PDB analysisChimeraXContact mapping
Publications & IP

Peer-reviewed work, patents, and preprints

Anal. Methods '25
Rapid On-Chip Nucleic Acid Extraction for Point-of-Care Salivary Diagnostics
Arockiam, S. et al. · Analytical Methods 17.21, 4321–4333
JCO Glob. Onc '25
Portable Detection of HPV for Cervical Cancer Screening in India: Translational Considerations for Global Health
Nguyen, V.T., Arockiam, S., Kumar, P. et al. · JCO Global Oncology 11, e2500117
SSRN · review
Chem. Eng. R&D '21
Mixing Efficiency in Serpentine Microdevices
Arockiam, S. et al. · Chemical Engineering Research and Design 167, 303–317
Biomicrofluidics '19
Effect of Electrode Configuration on Nucleic Acid Detection in Porous Interdigitated Electrodes
Cheng, Y.H. et al. (incl. Arockiam, S.) · Biomicrofluidics 13(6)
IEEE HI-POCT '24
Colorimetric On-Chip Detection of HPV for Point-of-Care Settings
Arockiam, S. et al. · IEEE HI-POCT 2024, 1–4 (oral)
Trajectory

Research & professional experience

Aug 2025 – Present

Postdoctoral Research Scholar

Biodesign Institute, Arizona State University

Computational genomics, translational oncology, and immunogenomics: neoepitope discovery pipelines, TB LAMP-Seq resistance detection, and high-throughput HPV screening on automated liquid handlers.

Aug 2020 – Aug 2025

Ph.D. · Graduate Research Assistant

Biodesign Institute, Arizona State University

Molecular diagnostics and point-of-care assay development. Dissertation on point-of-care diagnostics for early detection of HPV-driven cervical and oropharyngeal cancer. Advisors: Karen S. Anderson and Jennifer Blain Christen.

Apr 2018 – Aug 2020

Scientist II (Associate)

Merck & Co. · West Point, PA

Assay development and process optimization for live-attenuated VZV vaccines under cGMP. Flow cytometry potency assays, NanoString gene expression, and Quality Lead for FDA and multi-country regulatory audits.

Jan 2017 – Mar 2018

Research Assistant · M.S. Thesis

New Jersey Institute of Technology

Microfluidics and computational modeling: COMSOL fluid-dynamics models validated against experiment, blood-brain-barrier microdevices, and carbon-nanotube biosensors.

Nov 2015 – Mar 2016

Research Intern

National Institute for Research in Tuberculosis, Chennai

Developed LC-MS and RP-HPLC methods for pyrazinamide quantification in plasma for pharmacokinetic analysis (undergraduate thesis).

Beyond the Bench

Building, funding, and translating

Nucleate Arizona
Co-Founder & Director of Communications

Co-founded a student-led nonprofit accelerating biotech entrepreneurship in Arizona. Ran 10+ events for 400+ attendees, building bridges between academia and industry with AZBio and CEI.

SBIR Phase I · Awarded
Grant Development · 2025

Co-led an SBIR Phase I application for point-of-care HPV detection, awarded August 2025, and contributed technical sections to multiple NIH R21 and U01 proposals.

VC University · Cohort 16
Life Science Scholar · 2024

Full-tuition Life Science Scholarship for aspiring life-science investors. Venture Fellow at Laconia Capital, plus first place at the HonorHealth EHR hackathon.

Get in touch

Let's build something that reads biology and acts on it.

I am looking for postdoctoral and industry roles in computational immuno-oncology, ML for genomics, and translational diagnostics. If your work lives at that intersection, I would love to talk.